Denali Therapeutics Inc. — Director's Dealing 2021

Mar 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-03-03

Reporting Person: SATO VICKI L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-03	Common Stock	S	235	$60.36	Disposed	140518	Direct
2021-03-03	Common Stock	S	1050	$61.524	Disposed	139468	Direct
2021-03-03	Common Stock	S	266	$62.29	Disposed	139202	Direct
2021-03-03	Common Stock	S	115	$63.365	Disposed	139087	Direct

Footnotes

F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.

F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.02 to $60.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: The Reporting Person reported a prior award of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 3,253 previously reported restricted stock units.

F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $61.14 to $61.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $62.18 to $63.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.